12:00 AM
 | 
Jul 29, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Enhanced TCR Therapy: Phase I/II started

Adaptimmune began an open-label, U.S. Phase I/IIa trial to evaluate enhanced TCR therapy in about 6 patients with the human leukocyte antigen serotype A201 (HLA-A201)...

Read the full 115 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >